Global

Newsroom

RSS feed

Media Enquiries

Sharon McHale
Sharon McHale
Senior Director Public Affairs
CSL Limited
Phone: +613 9389 1506
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052 Australia

18/11/2014
CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated
Two research studies presented today at the American Heart Association Scientific Sessions in Chicago provide further understanding of the mechanisms by which CSL112, a novel formulation of apolipoprotein A-1 (apoA-1), may reduce the high incidence of early recurrent cardiovascular events seen in post MI patients. Early recurrent cardiovascular events are associated with high morbidity and mortality, and reducing early events is an important target for new therapies. More.

13/11/2014
New €350 Million Private Placement
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 12 November 2014 it closed a new €350 million private placement in the U.S. The private placement was foreshadowed in CSL’s full year announcement in August 2014. More.

10/11/2014
CSL Limited Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque
CSL Limited today announced the launch of AEGIS-I, a Phase 2b clinical study of CSL112, a novel formulation of apolipoprotein A-I (apoA-I). Administered as a short series of weekly infusions, CSL112 is designed to rapidly remove cholesterol from the arteries and stabilize lesions at risk of rupture. This represents a new approach to reduce the high incidence of early recurrent cardiovascular events in the days and weeks following a heart attack. More.

27/10/2014
CSL to acquire Novartis’ influenza vaccine business
CSL Limited has today announced an agreement to acquire Novartis’ global influenza vaccine business for US$275 million, which will be combined with CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL. More.

15/10/2014
CSL announces new A$950m share buyback
CSL Limited (ASX:CSL) today announced a new on-market share buyback of up to A$950 million. More.

08/10/2014
CSL announces major manufacturing expansion in Melbourne
CSL Limited (ASX:CSL) today announced a $210 million expansion of its CSL Behring manufacturing site in Broadmeadows (Melbourne) to help meet growing demand for its global critical care therapy, albumin. More.

13/08/2014
Full Year Results announcement for 2013/14
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,307 million for the full year ended 30 June 2014, up US$96 million or 8% on a reported basis when compared to the prior comparable period (PCP). The result includes a one-off U.S. antitrust class action litigation settlement. Earnings per share (EPS) grew 11%, benefiting from current and past capital management initiatives. More.

21/07/2014
bioCSL partners with Immucor to distribute global market-leading transfusion testing technology
bioCSL today announced that it has commenced distribution of Immucor Corporation’s global market‐leading “Capture®” technology platform and reagents in Australia and New Zealand. Capture® is an advanced antibody detection technology used in the cross‐matching of blood used for transfusion. More.

11/06/2014
International Medical Journal Publishes bioCSL’s Fluvax® Investigation Findings
The findings of bioCSL’s multi-year investigation into the cause of the unexpected adverse events associated with its Fluvax® influenza vaccine in 2010 were today published in two separate papers in the peer-reviewed journal Vaccine. More.

09/05/2014
CSL Opens Australian Biotechnology Manufacturing Facility
CSL Limited today officially opened the CSL Behring Biotechnology Manufacturing Facility in Broadmeadows, Melbourne. More.

12/02/2014
Half Year Results announcement for 2013/14
CSL Limited (ASX:CSL) today announced a net profit after tax (NPAT) of US$646 million for the six months ended 31 December 2013, up US$21 million or 3% on a reported basis when compared to the prior comparable period (PCP). The result included a one-off U.S. antitrust class action litigation settlement of US$64 million, or US$39 million after tax. More.

>> Prior Archived Newsroom


 

Media Enquiries - CSL Limited
Sharon McHale
Senior Director Public Affairs
Phone: +613 9389 1506
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052
Australia

Share
LinkedIn Twitter Facebook Google+